Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 485-140-4 | CAS number: 515815-48-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 13 October 1991 - 10 Novenber 1991
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted in GLP compliance andwas well described. BIBR 277 CL is the hydrochloride of BIBR 277 SE (Telmisartan, free acid). However, it is not evident from the study report which testing guideline was followed for the experiments.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The study was conducted in GLP compliance andwas well described. BIBR 277 CL is the hydrochloride of BIBR 277 SE (Telmisartan, free acid). However, it is not evident from the study report which testing guideline was followed for the experiments.
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- BIBR 277 SE
- IUPAC Name:
- BIBR 277 SE
- Test material form:
- not specified
- Details on test material:
- - Name of test material (as cited in study report): BIBR 277 SE
- Purity test date: 23 October 1991
- Lot/batch No.: 8110110
- Expiration date of the lot/batch: confirmed until October 31, 1992
- Stability under test conditions: guaranteed over 24 hrs
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: albino rats
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Karl Thomae GmbH, Biberach, Germany
- Age at study initiation: 46 days
- Weight at study initiation: 179 - 221 g
- Fasting period before study:
- Housing: housed individually in Makrolon (R) cages, Type III
- Diet (e.g. ad libitum): animals received a weekly food ration of pellets (NAFAG 8577)
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C +/- 3°C
- Humidity (%): 45 - 75 %
- Air changes (per hr): 16 / hour
- Photoperiod (hrs dark / hrs light): illumination at 100 lux from 7am - 4pm.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: suspension of hydroxycellulose (0.5%)
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- daily in the morning
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
10 mg/kg b.w. (G1)
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
50 mg/kg b.w. (G2)
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
100 mg/kg b.w. (G3)
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
200 mg/kg b.w. (G4)
Basis:
actual ingested
- No. of animals per sex per dose:
- each 10 m/10 f, and additionally 3m/3f animals per substance-treated group for toxicokinetic investigations.
An extra number of 10m /10f rats of the highest concentration group were used for a 5-weeks treatment-free recovery period. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: basing on results of a preliminary dose-finding study
- Rationale for animal assignment: random
- Rationale for selecting satellite groups: random
- Post-exposure recovery period in satellite groups: 5 weeks - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS:No data
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: physical signs: twice daily
BODY WEIGHT: Yes
- Time schedule for examinations: bw was determined once a week
FOOD EFFICIENCY:
- each animal was given a measured, adequate quantity of feed and water, calculated from the previous weeks consumption. Food/water intake was determined once a week, by weighing the remaining food/water.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: during weeks 4 (and 9 for additional recovery group)
- Dose groups that were examined: all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: before the start of administration and in week 4. recovery animals were also tested in week 9.
- Anaesthetic used for blood collection: Yes (halothane)
- Animals fasted:no
- How many animals: all
- Parameters checked in table: see attached study report.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: before the start of administration and in week 4. recovery animals were also tested in week 9.
- Animals fasted:no
- How many animals: all
- Parameters checked in table : see attached study report.
URINALYSIS: Yes
- Time schedule for collection of urine: in weeks 3 and 9 (recovery animals only)
- Metabolism cages used for collection of urine: Yes (URIMAX)
- Animals fasted: No data
- Parameters checked in table : see attached study report.
NEUROBEHAVIOURAL EXAMINATION: no
BONE MARROW EVALUATION:
At termination, bone marrow from 10 m/f animals from the high dose and control groups was evaluated. Since no pathological changes were observed, the smears of the other groups were not eaxmined.
TOXICOKINETICS:
Blood samples were collected from animals used specifically for the accompanying toxicokinetic investigations on the 1st and 14th study day and during the 4th week. - Sacrifice and pathology:
- PATHOLOGY:
- after sacrifice, the following organs of the animals were observed: heart/ lungs/ liver/ spleen/ thymus/ brain/ pituitary gland/ thyroid/ kidneys/ adrenals / gonads.
GROSS PATHOLOGY:
A complete autopsy was performed on all animals used in the study, all macroscopial changes were recorded, beginning on the day after the final adiminstration of the test solution.
HISTOPATHOLOGY:
the following organs and tissues were collected from all anomals, fixed in Bouin's solution or 10% buffered formalin.
heart/ lungs/ liver/ spleen/ kidneys / adrenals / esophagus/ stomach/ duodenum/ jejunum/ ileum/ colon/ cecum/ rectum/ pancreas/ brain/ pituitary/ thyroid with indent parathyroids/ thymus/ parotid gland/ submandibular salivary gland/ sublingal salivary gland/ lacrimal gland/ mesenteric lymph node/ cervical lymph node/ testes/ seminal vseicle/ epididymides/ prostate/ uterus/ ovaries/ urinary bladder/ skin/ eye and optical nerve/ mammary gland/ skeletal muscle/ tngue/ trachea/ aorta/ femur/ sternum/ bone marrow/ sciatic nerve/ spinal cord/ macroscopic lesions - Statistics:
- The following statistical algorithms were used:
BARTLETT test;
one-way analysis of variance; and
NEWMAN KEUL's test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly decreased in the 2 highest dose groups (males)
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- significantly decreased in the 2 highest dose groups (males)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- see details below
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- see details below
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment-related erosions of the stomach mucosa were observed in G2 (2m/2f), G3 (5m/2f), G4 (5m/3f).
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- see details below
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- see details below
- Details on results:
- CLINICAL CHEMISTRY:
at the end of the study, the values of urea nitrogen (f/m, all groups), creatinine (only m, all groups), potassium (males: all groups, females: groups 2-4) and magnesium (groups 3-4, f/m) were increased.
Furhtermore, in the male rats, the total cholesterol (G2-G4) was increased and a decrease in the total glycerol (G1-G4) was evident.
ORGAN WEIGHTS:
The following significant differences were observed:
Increase: kidneys (females G1, G3); adrenals (males G4 recovery), pituitary (males G4 recovery).
Decrease: heart (males G3, G4, females: G1-G4), pituitary (females G1, G3, G4) and thyroids (females G4).
TOXICOKINETICS:
see attached study report for details on plasma concentrations
HISTOPATHOLOGY:
mucosal erosions and ulcers of the glandular stomach were observed in animals of all groups. The injury of the stomach was found to be dose.dependant and reversible.
In the liver, a dose.related, sex.independent change developed, consisting of a harmless, patch-like basophilic appearance of the hepatocellular cytoplasm. This finding disappeared nearly completely at 5 weeks after drug withdrawal.
Hyperplasis of the renin- producing, granular epitheloid cells of the juxtaglomerular apparatus with prominent granularity were found in the kidneys. Except of the low-dose females, animals of all dose-groups were affected. These changes were more pronounced in males than in females and regressed after drug withdrawal.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- < 10 mg/kg bw (total dose)
- Based on:
- not specified
- Sex:
- male/female
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- No NOEL could be estimated as slight toxic signs (minore focal erosions) were already demonstrated in the lowest dosage group pf 10 mg/kg. Nevertheless, as this dosage yields plasma levels exceeding the presumed therapeutic levels by a factor of ten, the present experiment does not demonstrate any special risks for short term clinical trials in humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.